United Kingdom· GB-APID-32404611000001107
Farydak 20mg capsules
A panobinostat product containing panobinostat, registered in United Kingdom by pharmaand GmbH. The same ATC class is registered in 10 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Panobinostat is registered in 10 of 19 countries.
Countries holding a registration under ATC L01XH03 (panobinostat), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 7 of them publish a price we can compare per daily dose
Panobinostat · ATC L01XH03
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Panobinostat
- Manufacturer
- pharmaand GmbH
- Country
- United Kingdom (GB)
- ATC code
- L01XH03
- ATC class
- Panobinostat
- Defined daily dose
- 5.7 mg, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 3
- gtin5010678906127
- gtin00373116390021
- gtin9120099675611
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
586 interactions on record for panobinostat.
Graded by severity as the source publishes them — 388 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Panobinostat · interactions on record
586 records
- 388 severe
- 193 moderate
- 5 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Panobinostat in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaFARYDAKpharmaand GmbH, Vienna
- SwitzerlandFarydak 20 mg, Hartkapselnmmpharm GmbH
- FinlandFarydakpharmaand GmbH
- FranceFARYDAK 20 mg, gélulePHARMAAND (AUTRICHE)
- IrelandFarydak 20 mg hard capsulespharmaand GmbH
- IcelandFarydakPharmaand GmbH
- NetherlandsFarydak 20 mg harde capsuleszr pharma& GmbH
- NorwayFarydakpharmaand GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Farydak
- Liechtenstein · Farydak
- Norway · Farydak
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1a958ae3-a295-4fb4-b6b3-8d0c1f958f82 GET /v1/drugs/1a958ae3-a295-4fb4-b6b3-8d0c1f958f82?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "32404611000001107",
"desc": "Farydak 20mg capsules (pharmaand GmbH)",
"form": "Oral capsule",
"vpid": "32420011000001101",
"source": "dmd",
"vtm_id": "777058000",
"strength": "20 mg",
"substance": "Panobinostat",
"ingredient": "Panobinostat lactate anhydrous",
"supplier_code": "41622111000001102"
}See everything about panobinostat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.